NAFTA 2.0: Obstacles to More Affordable Meds
Patients in the U.S. are already confronted by the world’s longest climb to affordable biosimilar medicines. NAFTA 2.0 (USMCA) will eliminate easier routes and keeps drug prices out of reach for American patients. Learn more at: http://bit.ly/NAFTA-Obstacles-blog
NAFTA 2.0: 3 Obstacles to More Affordable Medicines in the U.S.
We are in the middle of an unprecedented national debate on the cost of prescription drugs. Republicans and Democrats are working together toward a shared goal of making medicines more affordable for America’s patients. And despite some vocal and predictable opposition, we may see real change. That is why it is so striking that Congress […]
AAM Statement on Signing of USMCA by President
WASHINGTON, DC (November 30, 2018) – AAM is extremely concerned that the USMCA, if left in its current form, will decrease prescription drug competition, inevitably leading to increased drug prices in the United States. This will harm American patients, job creators, workers and taxpayers. Furthermore, several provisions within the agreement are inconsistent with U.S. law […]
Op-Ed: The New NAFTA Could Thwart President’s Promise to Lower Prescription Drug Costs
President Trump has declared lowering our nation’s drug costs a high priority. But his renegotiated North American Free Trade Agreement, which has now been rebranded by Trump as the US-Mexico-Canada Agreement (USMCA), will actually prevent him from reducing the exorbitant costs of prescription drugs for America’s patients. That’s because a provision of the proposed agreement […]
AAM Opposes Barriers to Generic Drug and Biosimilar Access in Proposed US-Mexico-Canada Agreement (USMCA)
WASHINGTON DC (October 1, 2018) – AAM is extremely concerned that the proposed US-Mexico-Canada trade agreement will provide a windfall for brand-name drug manufacturers and raise prescription drug prices for patients in the United States. The proposed trade agreement USMCA fails to achieve one of the principle objectives of the Bipartisan Congressional Trade Priorities and Accountability […]
How a Renegotiated NAFTA Could Keep Drug Prices High for Patients
This fact sheet provides key takeaways and resources for lawmakers and was shared at the Capitol Hill briefing on September 14, 2018. Key Takeaways: U.S.–Mexico agreement on 10 years keeps brand drug prices high for longer A renegotiated NAFTA should lower – not increase – drug prices for patients Higher drug prices abroad ≠ lower […]
North American Generic Drugmakers Call for Rejection of New Exclusivity Period for Biologics
WASHINGTON DC (August 28, 2018) – Statement of the Association for Accessible Medicines, Canadian Generic Pharmaceutical Association, and Mexican Association of Generic Medicines on the Announcement U.S.-Mexico Understanding on Biologic Exclusivity The announced trade understanding between the U.S. and Mexico to extend brand name biologic data protection to ten years will harm patients who seek […]
